• +41 91 682 20 40
  • info@elixi-int.com
  • Reserved Area
    • Login
    • Register
    • Request Document
    • Send Document
logo
  • Home
  • About Us
  • Services
  • Quality
  • News
  • Case Studies
  • Contact

Let's talk

info@yourwebsite.com
+1 (555) 123-4567

  • Search

anti-aquaporin-4 (AQP4) antibody positive.

10 July 2019

FDA approves Soliris (eculizumab), first treatment for neuromyelitis optica spectrum disorder, a rare autoimmune disease of the central nervous system

by Elixi